Astellas' Vaprisol Receives Second Indication
This article was originally published in PharmAsia News
Executive Summary
FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2
You may also be interested in...
FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market
FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market
Astellas’ Vaprisol Approved For “Water Poisoning” Indication
Arginine vasopressin antagonist is the first drug indicated for the treatment of euvolemic hyponatremia.